Semaglutide is indicated for adults with type 2 diabetes mellitus (T2DM) who are receiving metformin and/or sulfonylureas in addition to diet control and exercise and whose blood glucose remains poorly controlled; For reducing the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with T2DM with cardiovascular disease.